Biogen logo Key Points Biogen's recent launches in Alzheimer’s, Friedreich’s ataxia, postpartum depression and ALS are now offsetting MS decline, with those growth drivers up 53% and contributing about $1.9 billion. Management completed a structural cost reset—about $1 billion in gross and $800 million net savings with ~15% headcount reduction and 26% lower R&D—while tightening portfolio discipline and reporting 10 Phase III programs and five potential new products. CEO Chris Viehbacher called 2026 ...